Idiopathic Pulmonary Fibrosis Advances in Diagnostic Tools and Disease Management /

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Nakamura, Hiroyuki (Επιμελητής έκδοσης), Aoshiba, Kazutetsu (Επιμελητής έκδοσης)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Tokyo : Springer Japan : Imprint: Springer, 2016.
• Έκδοση: 1st ed. 2016.
• Θέματα: Medicine.; Respiratory organs > Diseases.; Cytokines.; Growth factors.; Medicine & Public Health.; Pneumology/Respiratory System.; Cytokines and Growth Factors.

From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disea...

Πίνακας περιεχομένων:

• Part 1
• Definition, epidemiology, and pathogenesis
• Chapter 1: Definition of IPF  (Question: Is the latest classification [ATS/ERS] satisfactory?)
• Chapter 2: Epidemiology and risk factors of IPF  (Question: Can we dare to ask, “What are the possible causes?”)
• Chapter 3: Acute exacerbation of IPF  (Question: The concept was proposed in Japan, but why was it not recognized in western countries?)
• Chapter 4: Pathogenesis   (Question: Is abnormal repair of epithelial damage involved in the basic pathogenesis of this disease?)
• Part 2 Diagnosis   
• Chapter 5: Specific serum markers of IPF  (Question: What are the significances of KL-6, SP-A, and SP-D?)
• Chapter 6: High-resolution CT of honeycombing and IPF/UIP  (Question: To what extent can honeycomb lung be diagnosed by imaging? To what extent can IPF diagnosis be made by HRCT?)
• Chapter 7: Pathology of IPF  (Question: Why does the pathological classification of IIPs vary among pathologists?)
• Chapter 8: Differential diagnosis  (Question: What should we particularly keep in mind in the differential diagnosis?)
• Part 3 Management and prognosis   
• Chapter 9 Pharmacotherapy of IPF (antifibrotic compounds)  (Question: Can antifibrotic agents really inhibit fibrosis? How about the development of new therapeutic agents?)
• Chapter 10: Pharmacotherapy of IPF (Corticosteroids, immunosuppressants)  (Question: Are these actually effective? Ineffective? Harmful?)
• Chapter 11: Non-pharmacological therapy for IPF  (Question: Is respiratory care actually effective?)
• Chapter 12: Pharmacotherapy of acute exacerbation of IPF (Corticosteroids, immunosuppressants and direct hemoperfusion with polymyxin B)  (Question: Are high-dose steroid therapy, other immunosuppressant therapy, and PMX therapy [often used in Japan] really effective?)
• Part 4 Topics   
• Chapter 13 :Combined pulmonary fibrosis and emphysema (CPFE)  (Question: Is it an independent disease entity?)
• Chapter 14: Common pathways in IPF and lung cancer  (Question: Why is lung cancer associated with IPF at a high frequency?)
• Chapter 15 :Acute exacerbation of IIPs after pulmonary resection for lung cancer   (Question: Can acute exacerbation of IPF be predicted preoperatively?)           .